FDA Drops Two-Trial Requirement: A New Era for Addiction Treatment Drug Development

For more than half a century, pharmaceutical companies seeking FDA approval for a new drug faced a daunting standard: two independent, positive clinical trials. The requirement, rooted in 1960s drug regulation, was designed to minimize the risk of false positives—ensuring that a single lucky result wouldn't lead to widespread use of an ineffective or unsafe therapy.

On February 18, 2026, the FDA ended that era.

In a policy announcement published in the New England Journal of Medicine, FDA Commissioner Marty Makary and vaccine chief Vinay Prasad declared that one adequate and well-controlled clinical trial, supported by confirmatory evidence, will now generally be sufficient for drug approval. The change marks one of the most significant regulatory shifts in modern pharmaceutical oversight—and it could have profound implications for addiction medicine.

For developers of therapies targeting opioid use disorder, alcohol addiction, and stimulant dependence, the announcement represents an opportunity to bring treatments to market faster and at lower cost. For patients waiting years for new options, it could mean the difference between life and death.

But the policy also raises questions. What counts as "confirmatory evidence"? Will single trials be designed rigorously enough to protect patient safety? And in a field where treatment success has historically been defined narrowly—often as complete abstinence—how will regulators evaluate medications that reduce harm without eliminating use entirely?

The answers to those questions will shape the future of addiction pharmacotherapy.

Why the FDA Changed Course

The two-trial requirement was never written into law. It emerged from early interpretations of the 1962 Kefauver-Harris Amendment, which required manufacturers to prove drugs were both safe and effective through "adequate and well-controlled investigations"—plural.

For decades, FDA reviewers interpreted that language conservatively. Two trials meant lower risk of approving a treatment based on statistical noise. If one study showed benefit and another didn't, regulators could require a third tiebreaker. The system was cautious by design.

But science has changed. In the 1960s, drug development often involved testing compounds with poorly understood mechanisms of action. Today, therapies are designed based on detailed knowledge of molecular targets, biomarkers, and disease pathways. Trials are larger, more sophisticated, and statistically robust. Regulatory tools—accelerated approval pathways, real-world evidence databases, post-market surveillance systems—provide additional layers of oversight.

In 1997, Congress granted the FDA explicit authority to approve drugs based on a single adequate and well-controlled study combined with confirmatory evidence. That evidence can include mechanistic data, results in related conditions, animal studies, or real-world performance data. For rare diseases and oncology drugs, single-trial approvals have been common for years.

Makary and Prasad argue that it's time to extend that flexibility across the board.

"In this setting, over-reliance on two trials no longer makes sense," they wrote. "In 2026 there are powerful alternative ways to feel assured that our products help people live longer or better than requiring manufacturers to test them yet again."

The policy shift doesn't eliminate the two-trial option. Companies can still submit multiple studies if they choose. But it removes the default expectation, allowing sponsors to design more efficient development programs—especially for conditions where recruitment is difficult, patient populations are small, or existing treatments are inadequate.

Dr. Janet Woodcock, who led the FDA's drug center for two decades before retiring in 2024, told U.S. News that the scientific reasoning is sound. "As we move toward greater understanding of biology and disease, we don't need to do two trials all the time," she said.

The change, she noted, will have the greatest impact on drugs for common conditions that have historically been held to the two-trial standard. Cancer and rare diseases have already largely operated under single-trial flexibility. Addiction treatment falls squarely in the category of conditions that could benefit most.

What This Means for Addiction Medicine

The addiction treatment pipeline is crowded with promising candidates that have stalled in development due to the cost and complexity of conducting multiple large-scale trials.

Consider alcohol use disorder. Currently, only three medications are FDA-approved: disulfiram, naltrexone, and acamprosate. All three have been available for decades. None work for everyone. Yet despite growing understanding of the neurobiology of alcohol addiction, few new therapies have reached the market.

The situation is similar for stimulant use disorders. Methamphetamine and cocaine addiction affect millions of Americans, yet there are no FDA-approved medications for either condition. Behavioral therapies like contingency management show promise, but pharmacological options remain elusive.

Part of the problem is the economics of drug development. Running two large, multi-site randomized controlled trials can cost hundreds of millions of dollars. For conditions like opioid use disorder—where recruitment is challenging, dropout rates are high, and outcomes are measured over months or years—the financial and logistical burden is immense.

Under the new FDA policy, a company developing a medication for alcohol use disorder could potentially seek approval based on a single well-designed trial showing reduction in heavy drinking days, supported by mechanistic studies demonstrating how the drug acts on alcohol-responsive brain circuits. A therapy for stimulant addiction might be approved based on one trial showing reduced cocaine use, combined with real-world evidence from harm reduction programs.

The key word is "potentially." The FDA has made clear that single-trial approvals will not be rubber-stamped. Reviewers will scrutinize trial design, statistical power, endpoint selection, and the robustness of confirmatory evidence. Poorly designed studies will still be rejected, regardless of how many are submitted.

But for sponsors willing to invest in rigorous, well-controlled research, the pathway is now clearer—and shorter.

The Endpoint Problem: Abstinence vs. Harm Reduction

Even as the FDA loosens its trial count requirements, another debate is intensifying: how should success be measured?

Historically, the FDA has favored abstinence as the primary endpoint for addiction treatment trials. A medication is considered effective if it helps patients stop using drugs entirely, as measured by negative urine tests, self-reported abstinence, or sustained enrollment in treatment programs.

That standard reflects a traditional view of addiction recovery: the goal is to quit completely. But it creates a high bar for drug approval—one that many promising therapies fail to clear, even if they produce meaningful reductions in use or improvements in quality of life.

In recent years, researchers and patient advocates have pushed for a broader definition of treatment success. Harm reduction models emphasize that any decrease in drug use—even without total abstinence—can improve health outcomes. Reducing the frequency of heavy drinking, for example, lowers the risk of liver disease, accidents, and overdose. Cutting methamphetamine use from daily to weekly reduces the risk of psychosis, cardiovascular events, and infectious disease transmission.

In March 2025, NIDA Director Nora Volkow published an editorial arguing that reduction in drug use should be accepted as a valid endpoint in addiction treatment trials. "The FDA has historically favored abstinence as the endpoint," Volkow wrote, "but this approach may exclude medications that produce clinically meaningful harm reduction without achieving complete cessation."

The FDA has shown signs of flexibility. In 2021, the agency qualified a new endpoint for alcohol use disorder trials: the World Health Organization risk drinking level, which categorizes patients based on the number of heavy drinking days rather than requiring complete abstinence. The move signaled openness to harm reduction metrics.

The shift matters because it aligns regulatory expectations with the realities of addiction. Most people with substance use disorders do not achieve permanent abstinence on their first attempt—or even their fifth. Recovery is often a process of gradual reduction, relapse, and renewed effort. Medications that help people use less, even if they don't help everyone quit entirely, can still save lives.

Under the new single-trial policy, the choice of endpoint will be even more critical. A sponsor designing a study for cocaine addiction might propose measuring reductions in use frequency rather than abstinence. If the trial is well-powered, includes appropriate controls, and is supported by mechanistic data showing the drug reduces craving or withdrawal symptoms, it could form the basis for approval.

But that will require regulators to embrace a broader conception of treatment success—one that values harm reduction alongside abstinence.

Precision Medicine and the Genetic Factor

The move toward single-trial approvals dovetails with another trend reshaping addiction treatment: precision medicine.

Traditional addiction therapies are one-size-fits-all. Naltrexone, for example, is prescribed to millions of people with alcohol or opioid use disorder, but only about 30-40% respond meaningfully. For the rest, it does little. The problem is that addiction is not a monolithic condition. It arises from complex interactions between genetics, neurobiology, environment, and substance exposure.

Precision medicine seeks to match treatments to patients based on biological markers—genes, proteins, brain imaging patterns—that predict who will benefit.

One example is AD04, an investigational drug for alcohol use disorder developed by Adial Pharmaceuticals. The medication targets people with specific genetic variants that affect dopamine signaling. In a Phase 2 trial called ONWARD, patients carrying these variants showed significant reductions in heavy drinking when treated with AD04, while those without the variants did not benefit.

This is the kind of therapy the FDA's new policy is designed to accommodate. A single, well-designed trial in a genetically defined population could provide strong evidence of efficacy—especially when supported by mechanistic data showing why the drug works in that subgroup.

The challenge is that precision approaches require biomarker testing and patient stratification, which adds complexity and cost. But if regulators accept that a therapy doesn't need to work for everyone—just for a clearly defined population—the economics of development improve.

The FDA has already embraced precision oncology, approving dozens of cancer drugs based on biomarker-defined indications. Addiction medicine could be next.

What Developers and Clinicians Need to Know

For pharmaceutical companies, the message is clear: focus on trial quality, not quantity.

Under the new policy, reviewers will prioritize:

• Magnitude of effect: How large is the treatment benefit? A drug that reduces heavy drinking days by 50% is more compelling than one that reduces them by 10%.

• Control arm design: Are placebo controls appropriate? Should the comparator be standard of care rather than no treatment?

• Endpoint selection: Is the primary outcome clinically meaningful? Does it align with patient priorities and public health goals?

• Statistical power: Is the trial large enough to detect a true effect and rule out chance findings?

• Handling of missing data: Addiction trials often have high dropout rates. How are missing outcomes addressed?

• Biological plausibility: Does the drug act on a known pathway? Are there biomarkers or mechanistic studies supporting the proposed effect?

Companies that answer those questions convincingly will have a faster, cheaper route to approval. Those that rely on multiple weak studies will still face rejection.

For clinicians, the shift raises a different set of considerations. If single-trial approvals become more common, the burden of post-market evaluation increases. Real-world evidence—observational data from clinical practice—will play a larger role in confirming that drugs work as expected outside of controlled trial settings.

That means prescribers will need to stay informed about emerging safety signals, effectiveness data, and updates to drug labels. It also means participating in registries, reporting adverse events, and contributing to the evidence base that supports ongoing use.

The Risk of Moving Too Fast

Not everyone is celebrating the FDA's announcement.

Critics worry that reducing the evidence threshold could lead to approval of ineffective or unsafe drugs. A single trial, no matter how well-designed, can produce misleading results due to chance, bias, or undetected confounders. Requiring two independent studies reduces that risk by demanding replication.

Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School who studies drug regulation, told STAT News that the change "may sound reasonable in theory, but in practice it could erode confidence in the approval process."

Others point to the FDA's troubled history with accelerated approvals—a pathway that allows drugs to reach the market based on surrogate endpoints, with the requirement that companies conduct confirmatory studies afterward. In recent years, several high-profile cancer drugs approved under that pathway were later withdrawn because post-approval studies failed to demonstrate clinical benefit.

The concern is that a similar pattern could emerge under the single-trial policy. A drug approved based on one study and supportive mechanistic data might later turn out to be less effective—or more harmful—than initial evidence suggested. By the time that becomes clear, thousands of patients may already be using it.

Makary and Prasad have pushed back against those concerns, arguing that two poorly designed trials provide no more assurance than one rigorous study. "Without examination of the quality of a study, two trials may even provide a false assurance," they wrote.

The FDA has also emphasized that the policy does not weaken standards—it shifts the focus. Companies will still need to demonstrate safety and efficacy. The difference is that they can do so with one high-quality study plus corroborating evidence, rather than duplicating the same trial twice.

Whether that proves sufficient will depend on how rigorously the policy is implemented—and how transparent the FDA is about its decision-making.

A Turning Point for Addiction Pharmacotherapy

For decades, the addiction treatment field has lagged behind other areas of medicine in drug development. While cancer, cardiovascular disease, and diabetes have seen a steady stream of new therapies, addiction has remained stuck with a small handful of medications—many of them decades old.

The reasons are complex: stigma, reimbursement challenges, regulatory uncertainty, and the sheer difficulty of designing trials for conditions marked by relapse and variability. But one major barrier has been the cost and complexity of meeting FDA approval standards.

The February 18 policy announcement removes part of that barrier. By allowing single-trial approvals, the FDA has signaled that it is willing to accept more diverse forms of evidence—mechanistic data, real-world performance, biomarker studies—as substitutes for duplicative clinical trials.

That doesn't guarantee a flood of new addiction medications. Drug development is still expensive, risky, and time-consuming. But it does create a pathway that is faster and more flexible than before.

For patients struggling with opioid addiction, alcoholism, or stimulant dependence, that pathway could mean access to therapies that would otherwise never reach the market. For the families of the more than 100,000 Americans who die from overdoses each year, it could mean a chance at survival.

The FDA's job is to balance innovation with safety—to ensure that new drugs work without exposing patients to unacceptable risk. The shift to single-trial approvals recalibrates that balance, betting that rigorous evidence from one study, supported by complementary data, is sufficient to make informed decisions.

Whether that bet pays off will become clear in the coming years, as the first wave of therapies approved under the new policy reaches patients. If those drugs prove effective and safe, the change will be hailed as a breakthrough. If they don't, the FDA will face calls to reverse course.

For now, the door is open. The question is who will walk through it—and what they'll bring with them.